- Home
- CRAC vs SWKH Comparison
CRAC vs SWKH Comparison
Compare CRAC & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CRAC | SWKH |
|---|---|---|
| Founded | 2025 | 1996 |
| Country | Cayman Islands | United States |
| Employees | N/A | 9 |
| Industry | | Diversified Financial Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.0M | 198.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CRAC | SWKH |
|---|---|---|
| Price | $10.02 | $16.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 47.7K | 5.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $13.00 |
| 52 Week High | $10.05 | $18.66 |
Technical Indicators
Market Signals| Indicator | CRAC | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 62.38 | 48.34 |
| Support Level | $9.97 | $16.65 |
| Resistance Level | $10.05 | $17.03 |
| Average True Range (ATR) | 0.01 | 0.20 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 100.00 | 77.30 |
Price Performance
Historical ComparisonAbout CRAC Crown Reserve Acquisition Corp. I Class A Ordinary Shares
Crown Reserve Acquisition Corp I is a blank check company.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.